bpc 157 human clinical trial evidence safety regulatory status BPC-157 & The Gut-Brain Axis: A Practitioner's Definitive Review of the bpc-157 human clinical trials evidence
Description
Assessment was again carried out at the end of the subsequent 24 h period
A minimum of an 8 week cycle and a maximum of 12 weeks is recommended with injections administered once per week
Furthermore, 33% of participants treated with 162 mg oral doses twice daily showed a reduction of 50% in itch by week 10, with a suitable safety profile (161)
Moreover, Falla & Nagaraja (2010) found that application of GHKCu topical treatment has been associated with a ~27 % increase in hair density and Taub & Garrett (2011) reported a 70 % reduction in shedding within three months
